Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTER-EWING-1
jRCTs031260085Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- May 2026
- Modality
- Small Molecules
01
Overview
Randomised trial of regorafenib, vinorelbine and cyclophosphamide in Ewing sarcoma and round cell sarcoma (8 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: Induction chemotherapy EFS, Radiotherapy EFS (definitive radical) and 2 more. Started May 2026; status: recruiting.
02
Drugs
regorafenibvinorelbinecyclophosphamide
03
Conditions
Ewing sarcomaround cell sarcoma
Beyond the preview
Go deeper on jRCTs031260085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031260085.